19062-Lymphomas-NA-1270

Lymphomas

A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

  • Details

ClinicalTrials.gov ID: NCT04224493
Diagnosis Type: NA
USOR Number:

  • Address

11750 W 2nd Place, Suite 160
Lakewood, CO 80228
P: (303) 430-2700

Search by practice name, trial titles, indicators and specific disease types.